APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million

Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs

10-Jul-2024 - APEIRON Biologics AG announced that its shareholders have entered into a definitive agreement to sell their APEIRON shares to US-based Ligand Pharmaceuticals Incorporated for USD 100 million. APEIRON shareholders are also entitled to additional consideration based on future commercial and ...

APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01

Financing secures further clinical trials and the supply of material for the treatment of COVID-19 patients

03-Jun-2020 - APEIRON Biologics AG will complete a capital increase to finance the further development of APN01 for the treatment of severely ill COVID-19 patients as well as the development of immuno-oncology projects. The Vienna Insurance Group (VIG) will lead the financing round and secures the private ...

APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease

27-Feb-2020 - APEIRON Biologics AG announced the launch of a Pilot investigator-initiated clinical trial (IIT) with APN01, a recombinant human angiotensin-converting enzyme 2 (rhACE2), to treat patients with severe coronavirus infection in the People's Republic of China. The randomized, unblinded trial will ...

APEIRON: New CEO announced

18-Jul-2018 - APEIRON Biologics AG, a Vienna based biotechnology company founded by the Austrian molecular biologist Josef Penninger, which develops immuno-oncological therapies against cancer, announced today that after almost 13 successful years Dr. Hans Loibner (70) has handed over his position as CEO to ...

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

09-Jan-2018 - Evotec AG and APEIRON Biologics AG announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of EUR 3 m will be split equally between the two biotech companies. The success payment was triggered when the ...

Evotec, Apeiron Biologics and Sanofi develop novel cancer immunotherapies

11-Aug-2015 - Evotec AG and Apeiron Biologics AG announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies. This collaboration includes major research and development efforts to advance a first-in-class small molecule approach to treat solid and haematopoietic ...

Apeiron announces start of phase I trail with cellular anti cancer therapy

03-Mar-2015 - Apeiron Biologics AG announced that a first patient has been treated as part of a phase I clinical trial with Apeiron’s individual cellular therapy APN401. The investigator-initiated trial is performed at Wake Forest Baptist Medical Center (WFBMC) led by Pierre L. Triozzi, professor of internal ...

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy

07-Jan-2013 - Evotec AG announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration while ...

Apeiron initiates clinical study to investigate prevention of radiation-induced skin damage in breast cancer patientes

29-Feb-2012 - Apeiron Biologics AG announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Apeiron announced that a clinical trial has started with a liposomal topical ...

Start of Phase IIa study in acute lung injury patients marks development milestone for Apeiron's rhACE2

22-Dec-2011 - Apeiron announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron´s licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple ...